Medtronic (MDT) Competitors

In the previous week, Medtronic had 20 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 34 mentions for Medtronic and 14 mentions for GE HealthCare Technologies. Medtronic's average media sentiment score of 0.87 beat GE HealthCare Technologies' score of 0.71 indicating that Medtronic is being referred to more favorably in the media.

Medtronic currently has a consensus target price of $103.92, suggesting a potential upside of 19.22%. GE HealthCare Technologies has a consensus target price of $78.39, suggesting a potential upside of 17.95%. Given Medtronic's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medtronic is more favorable than GE HealthCare Technologies.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.3%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Medtronic pays out 70.9% of its earnings in the form of a dividend. GE HealthCare Technologies pays out 3.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has increased its dividend for 49 consecutive years and GE HealthCare Technologies has increased its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Medtronic has higher revenue and earnings than GE HealthCare Technologies. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Medtronic has a net margin of 13.93% compared to GE HealthCare Technologies' net margin of 9.33%. GE HealthCare Technologies' return on equity of 20.12% beat Medtronic's return on equity.

Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.3% of Medtronic shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Medtronic had 19 more articles in the media than Intuitive Surgical. MarketBeat recorded 34 mentions for Medtronic and 15 mentions for Intuitive Surgical. Intuitive Surgical's average media sentiment score of 0.88 beat Medtronic's score of 0.87 indicating that Intuitive Surgical is being referred to more favorably in the media.

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Intuitive Surgical has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Intuitive Surgical presently has a consensus target price of $508.68, indicating a potential upside of 23.41%. Medtronic has a consensus target price of $103.92, indicating a potential upside of 19.22%. Given Intuitive Surgical's higher possible upside, equities research analysts plainly believe Intuitive Surgical is more favorable than Medtronic.

Intuitive Surgical has a net margin of 28.45% compared to Medtronic's net margin of 13.93%. Intuitive Surgical's return on equity of 16.91% beat Medtronic's return on equity.

Medtronic has a net margin of 13.93% compared to Abbott Laboratories' net margin of 11.65%. Abbott Laboratories' return on equity of 17.69% beat Medtronic's return on equity.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.3%. Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.5%. Medtronic pays out 70.9% of its earnings in the form of a dividend. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medtronic has increased its dividend for 49 consecutive years and Abbott Laboratories has increased its dividend for 54 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and lower payout ratio.

Medtronic currently has a consensus target price of $103.92, indicating a potential upside of 19.22%. Abbott Laboratories has a consensus target price of $119.50, indicating a potential upside of 18.30%. Given Medtronic's higher probable upside, equities research analysts plainly believe Medtronic is more favorable than Abbott Laboratories.

In the previous week, Medtronic had 13 more articles in the media than Abbott Laboratories. MarketBeat recorded 34 mentions for Medtronic and 21 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.04 beat Medtronic's score of 0.87 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Abbott Laboratories has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of Medtronic shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medtronic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Boston Scientific has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Medtronic had 23 more articles in the media than Boston Scientific. MarketBeat recorded 34 mentions for Medtronic and 11 mentions for Boston Scientific. Medtronic's average media sentiment score of 0.87 beat Boston Scientific's score of 0.39 indicating that Medtronic is being referred to more favorably in the news media.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Boston Scientific has a net margin of 17.50% compared to Medtronic's net margin of 13.93%. Boston Scientific's return on equity of 19.28% beat Medtronic's return on equity.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Boston Scientific presently has a consensus price target of $70.19, indicating a potential upside of 60.46%. Medtronic has a consensus price target of $103.92, indicating a potential upside of 19.22%. Given Boston Scientific's higher possible upside, equities analysts plainly believe Boston Scientific is more favorable than Medtronic.